Opus Genetics Inc (IRD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.00-6.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IRD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.1% |
| Our one-year growth estimate | diamond | 17.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 72.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
IRD — officer change
Dated 2026-10-21
Chief Scientific and Development Officer — Ashwath Jayagopal: The Chief Scientific and Development Officer is departing the company, though the agreement includes a transition consulting period.
Why it matters: The company has said dosing is due in Q4 2026. A clear start update would show whether that plan is on track.
Watch forThe November 11 report confirms Phase 3 dosing has started, or gives a start date by December 31, 2026.
Also watch forThe report says dosing has not started and gives a start date after December 31, 2026, or no start window.
Why it matters: Starting the trial on time would keep the lead program on its stated path. A delay would push back a key test of the treatment.
Supportive ifThe company reports that OPGx-LCA5 Phase 3 dosing began by December 31, 2026.
Worry ifThe company reports that dosing did not start by December 31, 2026, or moves the start date later.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$243 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $732 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,922 loss on $10,000 · 49.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.